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Age is a signiﬁcant risk factor for the development of vascular diseases, such as atheroscle-
rosis. Although pharmacological treatments, including statins and anti-hypertensive drugs,
have improved the prognosis for patients with cardiovascular disease, it remains a leading
cause of mortality in those aged 65 years and over. Furthermore, given the increased life
expectancy of the population in developed countries, there is a clear need for alternative
treatment strategies. Consequently, the relationship between aging and progenitor cell-
mediated repair is of great interest. Endothelial progenitor cells (EPCs) play an integral role
in the cellular repair mechanisms for endothelial regeneration and maintenance. However,
EPCs are subject to age-associated changes that diminish their number in circulation and
function, thereby enhancing vascular disease risk. A great deal of research is aimed at
developing strategies to harness the regenerative capacity of these cells. In this review,
we discuss the current understanding of the cells termed “EPCs,” examine the impact of
age on EPC-mediated repair and identify therapeutic targets with potential for attenuating
the age-related decline in vascular health via beneﬁcial actions on EPCs.
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INTRODUCTION
Despite signiﬁcant advances in cardiovascular medicine over the
past decade, cardiovascular disease (CVD) remains the leading
cause ofmorbidity andmortality throughout the developedworld.
Aging is a major risk factor for the onset and progression of
CVD. The endothelium,which lines the lumen of all blood vessels,
plays a pivotal role in maintaining cardiovascular homeostasis.
This dynamic interface serves an enormous array of functions
including the regulation of coagulation, arterial tone, permeabil-
ity, vessel growth, and inﬂammation. As such, maintaining the
functional integrity of the endothelial monolayer is of crucial
importance for the prevention of CVDs, such as atherosclerosis.
However, a characteristic of the aging process is the development
of endothelial dysfunction, rendering the vasculature susceptible
to the development of atherosclerosis and subsequent cardiovas-
cular events. Although the mechanism of age-related impaired
endothelial function remains unclear, an imbalance between the
magnitude of vascular injury and the capacity for repair appears
to play a role. Accumulating evidence suggests that bone-marrow
derived circulating endothelial progenitor cells (EPCs) contribute
to vascular repair and regeneration. In settings of tissue ischemia
or endothelial damage, EPCs are mobilized from the bone mar-
row into the circulation and home to sites of vascular injury where
they are able to contribute to new blood vessel formation and aid
recovery. A deterioration of endogenous EPC function with age
may culminate in a decreased capacity for neovascularization of
ischemic tissues and/or reduced re-endothelialization of vascu-
lar lesions, facilitating the development, progression, and clinical
sequelae of atherosclerotic disease.
THE DISCOVERY OF CIRCULATING EPCs
Asahara et al. (1997) published the ﬁrst description of a candidate
EPC; CD34+ circulating cells capable of differentiating into cells
with endothelial characteristics and the ability to improve vascu-
larization in a mouse model of hind limb ischemia. This discovery
heralded a paradigm shift in vascular biology as it was recognized
that vasculogenesis, a process by which new blood vessels form de
novo through the differentiation of progenitor cells, and generally
accepted as being restricted to embryonic development, may con-
tribute to vascular repair and regeneration in adult life. The pos-
sibility of inducing new blood vessel formation and/or repairing
damaged vessels by delivering/recruiting EPCs is an attractive idea
that has stimulatedmuch interest among the scientiﬁc community.
However, contradictory ﬁndings regarding the origin, identiﬁ-
cation, and contribution of EPCs to the neoangiogenic process has
generated much debate within the ﬁeld. The controversy is largely
due to differences in the methodology used to isolate and culture
EPCs. Consequently, the term EPC has encompassed a host of dif-
ferent cell types,which unsurprisingly, have demonstrated amixed
ability to contribute to blood vessel formation and repair.
In general, three methods have been described to isolate and
expand EPCs from umbilical cord and peripheral blood mononu-
clear cells (MNCs; Figure 1; reviewed in Hirschi et al., 2008).
The ﬁrst method, originally described by Asahara et al. (1997)
involves the plating of MNCs on ﬁbronectin-coated tissue cul-
ture surfaces and re-plating the non-adherent cells after 48 h.
Colonies form after 4–9 days and have been termed early EPCs.
It is accepted that these are myeloid-derived cells that have a lim-
ited proliferative capacity and fail to form tube-like structures
in vitro. The ability of these cells to augment new blood vessel
formation appears to be through the production of angiogenic
growth factors, chemokines, and cytokines without direct incor-
poration into vascular networks (Hur et al., 2004). The second
approach involves plating MNCs on ﬁbronectin-coated dishes for
4 days, but this time keeping the adherent cells which give rise to a
heterogenous collection of cells termed circulating angiogenic cells
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FIGURE 1 | Methods of endothelial progenitor cell (EPC) isolation. (A)
Method 1: culture of early EPCs. Non-adherent MNCs are plated on
ﬁbronectin-coated tissue surfaces and form colonies after 4–9 days. These
colonies have been termed early EPCs and are comprised of round cells
surrounded by spindle-shaped cells. Image courtesy of Sahena Haque
(×40 magniﬁcation). (B) Method 2: culture of circulating angiogenic cells
(CACs). MNCs are plated on ﬁbronectin-coated tissue surfaces for 4 days
after which the non-adherent cells are removed. The adherent cells have
been termed CACs and do not typically display colony formation. Image
courtesy of John Reynolds (×20 magniﬁcation). (C) Method 3: culture of
outgrowth endothelial cells (OECs). MNCs plated on collagen I-coated
surfaces form colonies, termed OECs, with a cobblestone morphology
after 7–21 days of culture (×20 magniﬁcation). Adapted from Hirschi et al.
(2008).
(CACs). As with early EPCs, CACs express endothelial cell surface
antigens (Vasa et al., 2001) but also retain monocytic characteris-
tics and have a low proliferative potential (Rehman et al., 2003).
The third method of EPC isolation involves a longer period of
culture of MNCs on type I collagen coated surfaces. A population
of cells originate from the adherent cells between 7 and 21 days,
and have been referred to as outgrowth endothelial cells “OECs”
(Lin et al., 2000; Gulati et al., 2003). OECs uniformly express
endothelial markers, such as cluster of differentiation (CD) 31,
vascular endothelial (VE)-cadherin, vascular endothelial growth
factor receptor-2 (VEGFR-2), and uptake of acetylated low density
lipoprotein (AcLDL),but of note,unlike early EPCs andCACs, this
cell type is negative for hematopoietic or monocyte/macrophage
cell surface antigens CD45, CD14, and CD115. OECs are capable
of high rates of proliferation in vitro and vessel-forming activ-
ity when implanted in collagen gels in vivo (Ingram et al., 2004;
Melero-Martin et al., 2007; Yoder et al., 2007; Au et al., 2008).
Considerable effort has been devoted to distinguishing these
different cell types so that a deﬁnitive classiﬁcation of an EPC
phenotype can be established (Medina et al., 2010; Richardson
and Yoder, 2011). It is important to note, that to gain quantita-
tive data of putative circulating EPCs, ﬂow cytometric analysis,
in which EPCs are identiﬁed by cell surface phenotype, has been
widely used. However, as the ﬁeld has yet to reach agreement as
to the deﬁnitive phenotype(s) of an EPC, much debate surrounds
the choice of surface markers used in this approach. Indeed,many
studies reporting to quantify circulating EPCs have in fact quanti-
ﬁed hematopoietic cells with angiogenic capabilities (reviewed by
Mund and Case, 2011).
EPCs AND REDUCED VASCULAR REPAIR WITH AGE
The mobilization of EPCs from their bone-marrow niche appears
to constitute an integral part of the vascular homeostatic response,
since acute ischemic events, such as myocardial infarction
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(Shintani et al., 2001;Massa et al., 2005), acute coronary syndrome
(George et al., 2004), and vascular injury secondary to burns or
surgery (Gill et al., 2001) are associated with a signiﬁcant and
rapid increase in the levels of circulating EPCs. Consistent with
the notion that EPCs serve an integral role in cardiovascular repair
mechanisms,depletionof the circulatingEPCpool has been shown
to be a marker of cardiovascular damage and an independent pre-
dictor of cardiovascular events and death (Schmidt-Lucke et al.,
2005; Werner et al., 2005). Whether the decrease in EPC number
and impairment of function contributes to a loss of vasculopro-
tection, and the progression of CVD with age, remains to be fully
elucidated. However, the link between age and EPC dysfunction is
supported by a number of studies. Heiss et al. compared the num-
ber and function of early EPCs isolated from the peripheral blood
of healthy young and old (average ages of 25 and 61 years respec-
tively) individuals. Whilst there were no signiﬁcant differences in
the numbers of circulating EPCs (deﬁned as CD34+/KDR+ or
CD133+/KDR+) between the two groups, early EPCs from the old
subjects were found to be signiﬁcantly impaired in terms of prolif-
eration,migration, and survival (Heiss et al., 2005). Rauscher et al.
(2003) demonstrated that bone-marrow derived EPCs (deﬁned as
CD31+ CD45−) from young non-atherosclerotic ApoE−/− mice
reduced atherosclerotic plaque size inApoE−/− recipients despite
persistent hypercholesterolemia, an effect not detected when using
EPCs fromoldApoE−/−mice, thus suggesting that the atheropro-
tective properties of EPCs are diminished with age. In addition,
transplantation of bone-marrow derived EPCs from young, but
not old donormice,was seen to prevent a decline in the angiogenic
platelet-derived growth factor (PDGF)-B signaling and cardiac
angiogenesis in an aging murine model (Edelberg et al., 2002). It
is likely that the age-associated impairment of EPC number and
function is due to a variety of environmental changes that impair
EPC generation, mobilization from the bone marrow, homing,
and function, as well as intracellular alterations within the cells
that induce a senescent phenotype (Figure 2).
INCREASED EPC SENESCENCE WITH AGE
With advancing age most, if not all, mammalian cell types are
subject to internal alterations as well as environmental inﬂuences
that ultimately cause the cell to enter a state of irreversible growth
arrest, termed senescence. Internal changes include a reduction in
telomere length, a region of repetitive DNA sequences that serve
as the protective caps for chromosome ends. Telomere shortening
beyond a critical length leads to genomic instability and ultimately
cell cycle arrest. Decreased telomere length has been reported in
the leukocytes of patients with CVD, such as, chronic heart failure
(van der Harst et al., 2007), atherosclerosis (Samani et al., 2001),
and ventricular dysfunction (Collerton et al., 2007). A reduction
in telomere length with age has been shown in early EPCs of
healthy, sedentary men (Kushner et al., 2009) This is, in part, due
to an age-related decline in the expression of telomerase, a telom-
ere elongating reverse transcriptase enzyme. A 57% reduction in
FIGURE 2 | Endothelial progenitor cells in the aging vasculature.
A wide range of environmental and internal cellular changes occur
with advancing age that impair EPC numbers in circulation and
function at the site of injury. The generation, mobilization, and survival
of circulating EPCs are dependent on the presence of various
pro-angiogenic factors, estrogen, and nitric oxide, all of which are
known to decline with increasing age. Furthermore, the angiogenic
capacity of EPCs is also impaired with age owing to an increase in
oxidative stress, inﬂammation and the induction of a senescent
phenotype.
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early EPC telomerase activity was found in older men as com-
pared to younger counterparts (Kushner et al., 2011) and this is
further modulated by oxidative stress. EPC senescence induced by
telomere shortening may contribute to numerical and functional
impairments of EPCs and thus diminished endothelial regenera-
tion in the aging vasculature. Interestingly, overexpression of the
human telomerase reverse transcriptase (hTERT) gene in CACs
has been shown to conserve telomerase activity, delay cell senes-
cence, and enhance EPC reparative functions in amurine ischemic
hind limb model (Murasawa et al., 2002).
EPCs AND PRO-ANGIOGENIC FACTORS
An age-related decline in the expression of pro-angiogenic factors,
including growth factors, cytokines, andhormones, is likely to con-
tribute to impaired EPC generation, mobilization, migration, and
survival. The mobilization of EPCs from the bone marrow and
homing to sites of injury/neovascularization is dependent upon
a number of factors, including stromal derived factor-1 (SDF-1),
VEGF, granulocyte-colony stimulating factor (G-CSF), and estro-
gen. Decreased SDF-1 and VEGF expression in aged tissues has
been shown to impair EPC (Flk-1+/CD11b−) trafﬁcking to sites of
ischemia, and is related to depressed hypoxia-inducible factor-1α
(HIF-1α) signaling (Chang et al., 2007).
Premenopausal women have a lower risk of CVD than post-
menopausal women or age-matched men (Grady et al., 1992;
Grodstein et al., 1997). This is, in part, due to the dramatic decrease
in levels of the female reproductive hormone estrogen at the onset
of menopause. A number of studies have highlighted the role of
estrogen in EPC generation, mobilization from the bone marrow,
and incorporation at the sites of ischemia (Strehlow et al., 2003;
Hamada et al., 2006; Iwakura et al., 2006; Ruifrok et al., 2009).
Ovariectomy of young female mice was shown to signiﬁcantly
decrease the levels of EPCs (Sca-1+/Flk-1+) in the peripheral
blood and residing bone marrow, but this effect was prevented
by treatment with exogenous estrogen (Strehlow et al., 2003). In
addition to augmenting EPC generation and mobilization, estro-
gen has been shown to inhibit the senescence of CACs in vitro
by increasing telomerase activity, and also appears to promote
EPC proliferation and their incorporation into vascular networks
(Imanishi et al., 2005b).
The activity of a wide array of pro-angiogenic factors, includ-
ing VEGF, basic ﬁbroblast growth factor (bFGF), and SDF-1 is
modulated by cell surface heparan sulfate (HS) proteoglycans
(Fuster and Wang, 2010). Work from our laboratory suggests
that age-associated changes of HS structure on the surface of
OECs correlates with a signiﬁcant reduction inmigratory function
(Williamson et al., 2011).
EPCs AND OXIDATIVE STRESS
The progressive accumulation of oxidative damage with age, due
to increased production of reactive oxygen species (ROS) and
decreased expression of antioxidant proteins, also promotes senes-
cent cell changes. ROS lead to inactivation of nitric oxide (NO),
cause damage to proteins, lipids, and DNA, and alter cellular
redox state. Oxidative stress promotes the development of vas-
cular pathologies (Higgins et al., 2011; Sugamura and Keaney,
2011).With increasing age, it is likely that oxidative cellular damage
accumulates in EPCs, diminishing function and enhancing vascu-
lar disease risk. Early EPCs, CACs, and OECs have been shown
to express high levels of antioxidant enzymes and as a result,
are more resistant to oxidative stress, as compared with human
umbilical vein endothelial cells (HUVECs) and adult microvascu-
lar endothelial cells (Dernbach et al., 2004; He et al., 2004, 2009;
Cai et al., 2006). Such an enhanced antioxidant systemmay endow
EPCswith improved resistance to oxidative stress and thus the abil-
ity to promote vascular regeneration in settings of ischemic injury.
However, the antioxidant capacity of EPCs appears to be impaired
with age, for example, He et al. (2009) demonstrated that early
EPCs derived from old subjects had signiﬁcantly reduced levels
and activity of the antioxidant enzyme glutathione peroxidase-
1 (GPx-1) and were more sensitive to oxidative stress-induced
apoptosis as compared to EPCs of younger subjects. Together,
these factors may reduce EPC survival capacity and their ability to
promote endothelial repair in the aging host. Aging is also asso-
ciated with an upregulation of proatherogenic stimuli including
angiotensin II (Ang II) (Baylis et al., 1997;Wang et al., 2003),which
has been shown to enhance the production of ROS in early EPCs
and thereby accelerate cellular senescence (Imanishi et al., 2005a;
Endtmann et al., 2011). Moreover, treatment of coronary artery
disease patients with an Ang II type I receptor (AT1-R) antagonist
was found to signiﬁcantly increase the number of circulating EPCs
(CD34+/KDR+) (Endtmann et al., 2011).
A DECREASE IN NITRIC OXIDE BIOAVAILABILITY IN EPCs
WITH AGE
A decline in EPC levels and functionmay be related to the reduced
capacity of the aging endothelium to generate nitric oxide (NO)
and the increased production of ROS with age. The importance
of endothelial nitric oxide synthase (eNOS) expression, and sub-
sequent NO production, for EPC mobilization, was documented
in eNOS null mice by Laufs and colleagues. Here, physical exer-
cise, which increases NO bioavailability, was found to signiﬁcantly
increase EPCnumbers (Sca-1+/Flk-1+) while this effect was atten-
uated in eNOS null mice and wild type mice treated with an
NOS inhibitor (Laufs et al., 2004). The accumulation of oxidized
low density lipoprotein (ox-LDL) with age may also contribute
to a reduction in the number of circulating EPCs. ox-LDL has
been shown to impair early EPC survival and function, due to its
inhibitory effect on EPC eNOS expression and activity (Ma et al.,
2006).
EPCs AND INFLAMMATION
Aging is known to be associated with the development of chronic
low grade inﬂammation, which renders the vasculature suscepti-
ble to the development of CVD (Csiszar et al., 2008). Among the
proinﬂammatory changes that occur with increasing age, dysreg-
ulation of the proinﬂammatory cytokine tumor necrosis factor-
alpha (TNF-α) has been well established (Csiszar et al., 2003,
2004, 2007). This multifunctional proinﬂammatory cytokine is a
key player in the pathogenesis of atherosclerosis. Indeed increased
circulating levels of TNF-α is associated with a high prevalence
of atherosclerosis in elderly patients (Bruunsgaard et al., 2000).
Chronic TNF-α treatment has been found to induce premature
senescence of highly proliferative OECs, which was related to an
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increase in expression of the cell cycle inhibitor p16INK4a (Zhang
et al., 2009). Thus, the shift to a proinﬂammatory state in the aged
vasculature may contribute to EPC dysfunction and a reduced
regenerative potential.
CONCLUDING REMARKS
Although age-related CVD may have multifactorial etiologies,
a common element appears to be the deterioration of endoge-
nous EPC function. Understanding EPC biology and identifying
strategies to restore the factors that are depleted or impaired
with age may provide a protective beneﬁt to the cardiovascu-
lar system and limit vascular disease progression in the aging
population. Indeed, pharmacological treatments including statins
(Landmesser et al., 2004), estrogen (Iwakura et al., 2003, 2006),
and peroxisome proliferator-activated receptor gamma agonists
(Redondo et al., 2007; Werner et al., 2007) have been shown to
augment EPC number and function, by increasing NO bioavail-
ability in EPCs, among other mechanisms of action. Treatment
with angiotensin receptor antagonists have been shown to reduce
oxidative stress in EPCs and augment function by blocking the
effect of AngII (Bahlmann et al., 2005). Other pharmacological
strategies to reverse age-related EPC dysfunction include growth
hormone treatment to increase insulin-like growth factor-1 (IGF-
1) levels, the synthesis of which is attenuated with aging (Thum
et al., 2007). Lifestyle modiﬁcations, such as regular aerobic exer-
cise or cessation of smoking, are known to promote vascular health
in the aging population and have direct effects on EPC number
and function. Reports suggest that physical exercise increases the
number and re-endothelialization capacity of EPCs in previously
sedentary older men (Hoetzer et al., 2007; Xia et al., 2011; Yang
et al., 2011), while smoking cessation has been found to induce
rapid restoration of EPC levels (Kondo et al., 2004). Although
long term follow up is necessary, these ﬁndings suggest that it is
possible to increase EPC number and function in the aging host by
restoring the pathways that govern EPC generation, mobilization,
and homing. Such approaches have potential for attenuating the
age-related decline in vascular health and improving the outcomes
for older individuals with CVD. However, further work is needed
to overcome the challenges associated with engraftment of these
cells to the damaged tissue and the resulting cross-talk with the
host endothelium andmedial cells that will ultimately result in the
repair of the damaged tissue.
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